Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ: TXG ) with a Neutral and raises the price target from $20 to $42.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.